Navigation Links
Micromet to Present at the 16th Annual NewsMakers in the Biotech Industry Conference on September 16, 2009
Date:9/15/2009

s and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of blinatumomab and other product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal qua
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... uBiome, Inc. has announced the ... clinical tests based on its unique microbial assays. ... sparked the era of microbiome-based personalized medicine by ... information about their own bodies using the latest ... uBiome has gathered millions of data points in ...
(Date:4/28/2015)... 2015 Dr. Harton will be responsible ... service operations across the products of Fertility Authority.com, EggBanxx, ... and only FDA-cleared test to use time lapse imaging ... selection during IVF. , Dr. Harton has joined Progyny ... Sciences, including both laboratory management and IVF practice management ...
(Date:4/27/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... year ended December 31, 2014. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... provide the outcome management and investors had hoped ... Therapeutics", said Andrew Rae , President & ...
(Date:4/27/2015)... BRUNSWICK, New Jersey , 27 ... société de découverte médicamenteuse spécialisée dans ... antibiotiques destinés à soigner les infections ... aujourd,hui la présentation de données prouvant ... majeur, le TXA709, dans la lutte ...
Breaking Biology Technology:uBiome Launches Clinical Laboratory 2Progyny Appoints Gary Harton as Group Senior Vice President, Commercial Development 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6
... Inc. announced today that it has initiated patient enrollment ... lead product candidate TG-C.  TG-C involves human allogeneic chondrocytes ... regeneration of cartilage in patients suffering from severe osteoarthritis ... placebo-controlled Phase II study will evaluate the safety and ...
... animals grew far more complex than their single-celled ancestors. ... finds that complex organisms, including humans, have accumulated structural ... from microbe to man. The study, published in ... errors into proteins, rather than traditional natural selection, may ...
... 2011 Cellectis bioresearch, a subsidiary of Cellectis ... Wako Pure Chemical Industries as its distributor in ... products and services, including the recently launched TALEN(1) ... distributor of research products in Japan. ...
Cached Biology Technology:TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee 2Errors in protein structure sparked evolution of biological complexity 2Errors in protein structure sparked evolution of biological complexity 3Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan 2
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... 14, 2012) A research team has identified epigenetic ... gene expression, within reprogrammed skin cells. These signatures can ... skin cells or induced pluripotent stem cells (iPSCs), cells ... the expression of the protein is controlled brings us ...
... GABLES, FL (March 14, 2012)--Convincing speeches are central to campaigning ... select our leaders? A newly-published paper in Proceedings of ... and women vote for male and female candidates with lower-pitched ... to be perceived as more competent, stronger, and more trustworthy. ...
... to testicular cells than titanium dioxide nanoparticles, according to ... Health. However, the use of both types may affect ... Commonly used Nanotechnology is increasingly ... potential risks of using engineered nanoparticles need to be ...
Cached Biology News:Epigenetic signatures direct the repair potential of reprogrammed cells 2Are silver nanoparticles harmful? 2
... The Oxidized LDL Competitive ELISA is ... in the sample competes with a fixed amount ... for the binding of the biotin- labeled specific ... 25 l The Oxidized LDL Competitive Enzyme-Linked ...
... For nucleofection of optimized cell lines ... protocol including the nucleofection parameters. Nucleofector ... with the Nucleofector Device., Different cell ... kit. The corresponding efficiencies and viabilities ...
... that is designed for use with HRP conjugated ... a mouse monoclonal coating antibody. • ... to prevent non-specific binding between the coating and ... buffer may be used to stabilize newly conjugated ...
... in solution or in a gel piece, we ... will be digested to produce a mixture of ... are determined by MALDI-TOF, and the amino acid ... MALDI-TOF will be determined by MALDI-TOF/TOF. The masses ...
Biology Products: